By blocking the PD-1/PD-L1 interaction and restoring the effector function of PD-1+ T cells [12], anti-PD-1 therapy restores T lymphocyte cytotoxicity directed against antigens to effectively destroy tumour cells [5]. Here, PDCD1 is linked to neoplasm.